NEW YORK (GenomeWeb) – Singulex has shipped its first Singulex Clarity system — an immunodiagnostics platform based on single-molecule counting technology — to a laboratory in Barcelona, which will validate the instrument for use as a CE-marked in vitro diagnostic system in Europe.

In addition, Singulex is planning to begin clinical studies in the US this July designed to bring the Clarity system through US Food and Drug Administration 510(k) clearance, Singulex CEO Guido Baechler recently told GenomeWeb.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.